WARF TECHNOLOGIES

UW researchers have identified the combination of TLR3 and TLR9 agonists as the most effective means of activating T cells and induing anti-tumor activity when used with a DNA vaccine to treat prostate cancer. Researchers have reported and companies have patented various combinations of TLR agonists as useful in increasing vaccine efficacy against pathogens and various cancers. Looking at various combinations and studying the underlying mechanisms of immuno-stimulatory activity, the researchers postulated that TLR3 and TLR9 agonists in combination would be the most effective stimulators of an immune response in combination with a DNA vaccine. They validated that hypothesis in cultured cells.

For More Information About the Inventors

• Douglas McNeel

Tech Fields

• Therapeutics & Vaccines : Vaccines